Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet]

Susan L Norris  1 , Nancy J Lee  1 , Susan Severance  1 , Sujata Thakurta  1 , Benjamin Chan  1
Portland (OR): Oregon Health & Science University; 2008 Aug.
Drug Class Reviews.
Affiliations
Free Books & Documents
Review

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet]

Susan L Norris et al.
Free Books & Documents

Excerpt

Diabetes mellitus (diabetes) is a chronic and insidious disease affecting more than 20 million Americans, approximately 7% of the population. Within the last 1 to 2 years, three new antihyperglycemic agents have been approved: pramlintide, exenatide, and sitagliptin. These agents offer mechanisms of glycemic control beyond that of "traditional" oral agents and insulin by targeting alternate gluco-regulatory receptors and hormones such as amylin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and dipeptidyl peptidase-4 (DPP-4). The purpose of this review was to compare the effectiveness and harms of newer diabetes medications for persons with diabetes mellitus.

PubMed Disclaimer

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 14 organizations, including 13 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

LinkOut - more resources